Hokkaido’s Kamui Pharma Co. starts on probiotic R&D

The focus of the venture, established in April 2018, is to develop microbial therapies for inflammatory bowel diseases.

Nikkei Biotech news release, July 4, 2018

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny